专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3079666B1 PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE 有权
公开(公告)号：EP3079666B1
公开(公告)日：2021-02-03
申请号：EP14809821.3
申请日：2014-12-05
发明人： PLANELLS JIMENEZ, Maria , DUARTE LOPEZ, Begoña , GUIRO COLL, Pere
IPC分类号： A61K9/16 , A61K9/28 , A61K31/225

2. 发明公开

EP3307272A1 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS 审中-公开
标题翻译：作为JAK抑制剂的2-（吡唑并吡啶-3-基）嘧啶衍生物
公开(公告)号：EP3307272A1
公开(公告)日：2018-04-18
申请号：EP16728326.6
申请日：2016-06-10
申请人： Almirall, S.A.
发明人： ESTEVE TRIAS, Cristina , TALTAVULL MOLL, Joan , GONZALEZ RODRIGUEZ, Jacob , VIDAL JUAN, Bernat
IPC分类号： A61K31/506 , A61K31/5377 , A61P3/00 , A61P5/00 , A61P9/00 , A61P11/00 , A61P17/00 , A61P25/00 , A61P31/12 , A61P35/00 , A61P37/00 , C07D471/04
CPC分类号： C07D471/04 , C07D239/24
摘要： New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of Janus Kinases (JAK).

3. 发明授权

EP2961407B1 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH 2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES 有权
标题翻译：具有2肾上腺素能受体激动剂和M3肌肉受体拮抗剂活性的2-氨基-1-羟乙基-8-羟基喹啉-2（1H） - 酮衍生物的盐
公开(公告)号：EP2961407B1
公开(公告)日：2018-04-11
申请号：EP14706652.6
申请日：2014-02-27
申请人： Almirall S.A.
发明人： CARRERA CARRERA, Francesc , PAJUELO LORENZO, Francesca , PEREZ ANDRES, Juan Antonio , PRAT QUIÑONES, Maria , PUIG DURAN, Carlos , JULIA JANE, Montserrat
IPC分类号： A61K31/4709 , C07D409/14 , A61P11/00
CPC分类号： C07D409/14 , A61K9/0073 , A61K9/0075 , A61K31/4709 , A61K45/06 , C07B2200/13 , C07C59/255 , C07C309/05 , C07D275/06 , A61K2300/00
摘要： The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a hydroxycarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.

4. 发明公开

EP3082753A1 TOPICAL PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING OCTENIDINE DIHYDROCHLORIDE 审中-公开
标题翻译：局部用药物和化妆品组合物奥替尼
公开(公告)号：EP3082753A1
公开(公告)日：2016-10-26
申请号：EP14816228.2
申请日：2014-12-17
申请人： Almirall, S.A.
发明人： TROMMER, Hagen , STRAHINJIC, Ivana , MALLWITZ, Henning , EVERS, Dirk , WILLERS, Christoph
IPC分类号： A61K8/49 , A61Q19/00 , A61K9/00 , A61K9/107 , A61K31/4425
CPC分类号： A61K9/0014 , A61K8/4926 , A61K9/107 , A61K31/444 , A61Q19/007
摘要： Topical pharmaceutical or cosmetic compositions are described comprising octenidine dihydrochloride. Said compositions are stable and can be safely and easily applied over large surface areas of the skin in an acceptable way by the general patient population for the treatment or prevention of some skin disorders or diseases.

5. 发明公开

EP3079666A1 PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE 有权
标题翻译：药物组合物与二甲
公开(公告)号：EP3079666A1
公开(公告)日：2016-10-19
申请号：EP14809821.3
申请日：2014-12-05
申请人： Almirall S.A.
发明人： PLANELLS JIMENEZ, Maria , DUARTE LOPEZ, Begoña , GUIRO COLL, Pere
IPC分类号： A61K9/16 , A61K9/28 , A61K31/225
CPC分类号： A61K31/225 , A61K9/1623 , A61K9/2018 , A61K9/2054 , A61K9/2846
摘要： Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastro-resistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders.

6. 发明公开

EP2988745A1 COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS 审中-公开
标题翻译： KOMBINATIONEN MIT MABA-VERBINDUNGEN UND CORODOSTEROIDEN
公开(公告)号：EP2988745A1
公开(公告)日：2016-03-02
申请号：EP14707986.7
申请日：2014-02-27
申请人： Almirall S.A.
发明人： APARICI VIRGILI, Monica , CALBET MURTRO, Marta , MIRALPEIX GUELL, Montserrat , GAVALDA MONEDERO, Amadeu , PUIG DURAN, Carlos
IPC分类号： A61K31/4709 , A61K31/56 , A61K31/58 , A61P11/00
CPC分类号： A61K31/4709 , A61K9/0075 , A61K9/008 , A61K31/56 , A61K31/573 , A61K31/58 , A61K45/06 , C07D409/14 , A61K2300/00
摘要： A combination which comprises (a) corticosteroid and (b) a dual muscarinic antagonist - β2 adrenergic agonist compound, or any pharmaceutically acceptable salt or solvate thereof.
摘要翻译：一种组合，其包含（a）皮质类固醇和（b）双毒蕈碱性拮抗剂 - 肾上腺素能激动剂化合物或其任何药学上可接受的盐或溶剂化物。

7. 发明授权

EP2702061B9 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS 有权
标题翻译：作为PI3K抑制剂的吡咯并三嗪酮衍生物
公开(公告)号：EP2702061B9
公开(公告)日：2016-02-24
申请号：EP12717685.7
申请日：2012-04-26
申请人： Almirall S.A.
发明人： BERNAL ANCHUELA, Francisco Javier , CARRASCAL RIERA, Marta , CATURLA JAVALOYES, Juan Francisco , GRACIA FERRER, Jordi , MATASSA, Victor Giulio , TERRICABRAS BELART, Emma , TALTAVULL MOLL, Joan , ERRA SOLA, Montserrat
IPC分类号： C07D473/34 , C07D487/04 , A61K31/4985 , A61K31/437 , A61P35/00
CPC分类号： C07D487/04 , A61K31/53 , A61K45/06 , C07D473/34

8. 发明公开

EP2954891A1 INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF ASTHMA 有权
标题翻译：吸入组合物治疗哮喘的临床研究
公开(公告)号：EP2954891A1
公开(公告)日：2015-12-16
申请号：EP15173011.6
申请日：2009-03-13
申请人： Almirall, S.A.
发明人： LAMARCA CASADO, Rosa , DE MIQUEL SERRA, Gonzalo
IPC分类号： A61K9/14 , A61K9/72 , A61K31/46 , A61K45/06 , A61K9/00
CPC分类号： A61K31/439 , A61K9/0075 , A61K31/167 , A61K31/46 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 µg aclidinium bromide.
摘要翻译：用于吸入的药物组合物包含药学上可接受的盐的干粉形式的阿地喹鎓与药学上可接受的干粉载体的混合物，提供相当于约400μg阿地溴铵的计量标称剂量的阿地啶铵。

9. 发明授权

EP2389197B1 COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS 有权
标题翻译：结合甲氨蝶呤和DHODH抑制剂EMBRACE
公开(公告)号：EP2389197B1
公开(公告)日：2014-06-18
申请号：EP10701206.4
申请日：2010-01-19
申请人： Almirall S.A.
发明人： GODESSART MARINA, Nuria , PIZCUETA LALANZA, Maria, Pilar
IPC分类号： A61K45/06 , A61K31/519 , A61K31/44 , A61P29/00
CPC分类号： A61K31/44 , A61K31/519 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The present invention provides a combination which comprises (a) methotrexate and (b) a non-hepatotoxic DHODH inhibitor of formula (I): wherein: R 1 is selected from the group consisting ofhydrogen atoms, halogen atoms, C 1-4 alkyl, C 3-4 cycloalkyl, -CF 3 and -OCF 3 , R 2 is selected from the group consisting of hydrogen atoms, halogen atoms and C 1-4 alkyl groups, R 3 is selected from the group consisting of -COOR 5 , -CONHR 5 , tetrazolyl, -SO 2 NHR 5 and -CONHSO 2 R 5 groups, wherein R 5 is selected from the group consisting of a hydrogen atom and linear or branched C 1-4 alkyl groups, R 4 is selected from the group consisting of a hydrogen atom and a C 1-4 alkyl group, R 9 is selected from the group consisting of a hydrogen atom and a phenyl group, G 1 represents a group selected from N and CR 6 wherein R 6 is selected from the group consisting ofhydrogen atoms, halogen atoms, C 1-4 alkyl, C 3-4 cycloalkyl, C 1-4 alkoxy, - CF 3 , -OCF 3 , monocyclic N-containing C 5-7 heteroaryl, monocyclic N-containing C 3-7 heterocyclyl groups and C 6-10 aryl groups which C 6-10 aryl groups are optionally substituted with one or more substituents selected from halogen atoms and C 1-4 alkyl groups, G 2 represents a group selected from: €¢ a hydrogen atom, a hydroxy group, a halogen atom, a C 3-4 cycloalkyl group, a C 1-4 alkoxy group and NR a R b , wherein R a represents a C 1-4 alkyl group and R b is selected from a group consisting of C 1-4 alkyl group and C 1-4 alkoxy-C 1-4 alkyl group, or R a and R b together with the nitrogen atom to which they are attached form a saturated 6 to 8 membered heterocyclic ring optionally containing one oxygen atom as an additional heteroatom, €¢ a monocyclic or bicyclic 5 to 10 membered heteroaromatic ring containing one or more nitrogen atoms which is optionally substituted by one or more substituents selected from halogen atoms, C 1-4 alkyl, C 1-4 alkoxy, C 3-4 cycloalkyl, C 3-4 cycloalkoxy, -CF 3 , -OCF 3 , and -CONR 7 R 8 , wherein R 7 and R 8 are independently selected from hydrogen atom, linear or branched C 1-4 alkyl groups, C 3-7 cycloalkyl groups, or R 7 and R 8 together with the nitrogen atom to which they are attached form a group of formula wherein n is an integer from 0 to 3, and €¢ a phenyl group which is optionally substituted by one or more substituents selected from halogen atoms, C 1-4 alkyl, hydroxyl, C 1-4 alkoxy, C 3-4 cycloalkyl, C 3-4 cycloalkoxy, cyano, -CF 3 , -OCF 3 , -CONR 7 R 8 , oxadiazolyl, triazolyl, pyrazolyl and imidazolyl groups, which oxadiazolyl, triazolyl, pyrazolyl and imidazolyl groups are optionally substituted by C 1-4 alkyl or C 3-7 cycloalkyl groups and wherein R 7 and R 8 are independently selected from hydrogen atom, linear or branched C 1-4 alkyl groups, C 3-7 cycloalkyl groups, or R 7 and R 8 together with the nitrogen atom to which they are attached form a group of formula wherein n is an integer from 0 to 3 or, when G' represents CR 6 , G 2 together with R 6 forms a non-aromatic C 5-10 carbocyclic group or a C 6-10 aryl group, and the pharmaceutically acceptable salts and N-oxides thereof.

10. 发明公开

EP2641900A1 Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. 审中-公开
标题翻译： Neuartige polymorphe Kristallformen von 5-（2 - {[6-（2,2-二氟-2-苯基乙氧基）己基]氨基} -1-羟乙基）-8-羟基喹啉-2（1H） - 酮，Heminapadisylat als Agonist des beta2 - 肾上腺素受体
公开(公告)号：EP2641900A1
公开(公告)日：2013-09-25
申请号：EP12382101.9
申请日：2012-03-20
申请人： Almirall, S.A.
发明人： Amat Mestres, Gemma , Balaguer Ardanuy, Elvira , Carrera Carrera, Francesc , Marchueta Hereu, Iolanda , Moyes Valls, Enrique
IPC分类号： C07D215/26 , A61K31/4704 , A61P11/00
CPC分类号： C07D215/227 , A61K31/4704 , A61K45/06 , C07B2200/13 , C07D215/26
摘要： The present invention is directed to novel polymorphic crystal forms of a 5-{2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, methods of using them to treat respiratory diseases associated with β2 adrenergic receptor activity and a process for preparing such polymophic crystal forms.
摘要翻译：本发明涉及5- {2 - {[6-（2,2-二氟-2-苯基乙氧基）己基]氨基} -1-（R） - 羟乙基）-8-羟基喹啉-2-酮的新型多晶型物， 2（1H） - 酮，半淀粉二甲酸酯。本发明还涉及包含所述多晶型晶形的药物组合物，使用它们治疗与β2肾上腺素能受体活性相关的呼吸系统疾病的方法和制备这种多晶型晶形的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式